Literature DB >> 12832399

Opposing roles of Ras/Raf oncogenes and the MEK1/ERK signaling module in regulation of expression and adhesive function of surface transglutaminase.

Sergey S Akimov1, Alexey M Belkin.   

Abstract

Tissue transglutaminase (tTG) serves as a potent and ubiquitous integrin-associated adhesion co-receptor for fibronectin on the cell surface and affects several key integrin functions. Here we report that in fibroblasts, activated H-Ras and Raf-1 oncogenes decrease biosynthesis, association with beta1 integrins, and surface expression of tTG because of down-regulation of tTG mRNA. In turn, the reduction of surface tTG inhibits adhesion of H-Ras- and Raf-1-transformed cells on fibronectin and, in particular, on its tTG-binding fragment I(6)II(1,2)I(7-9), which does not interact directly with integrins. Analysis of Ras/Raf downstream signaling with specific pharmacological inhibitors reveals that the decrease in tTG expression is mediated by the p38 MAPK, c-Jun NH2-terminal kinase, and phosphatidylinositol 3-kinase pathways. In contrast, increased activation of the ERK pathway by constitutively active MEK1 stimulates tTG mRNA expression, biosynthesis, and surface expression of tTG, whereas MEK inhibitors or dominant negative MEK1 exert an opposite effect. This modulation of surface tTG by ERK signaling alters adhesion of cells on fibronectin and its fragment that binds tTG. Furthermore, transient stimulation of ERK signaling in untransformed fibroblasts by adhesion on fibronectin or growth factors elevates tTG biosynthesis, increases complex formation with beta1 integrins, and raises surface expression of tTG. Finally, ERK activation is required for growth factor-induced redistribution of tTG on the surface of adherent fibroblasts and co-clustering of beta1 integrins and tTG at cell-matrix adhesion contacts. Together, our data indicate that down-regulation of surface tTG by Ras and Raf oncogenes contributes to adhesive deficiency of transformed fibroblasts, whereas stimulation of biosynthesis and surface expression of tTG by the MEK1/ERK module promotes and sustains cell-matrix adhesion of untransformed cells. Contrasting effects of Ras/Raf oncogenes and their immediate downstream signaling module, MEK1/ERK, on tTG expression are consistent with adhesive function of surface tTG.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12832399     DOI: 10.1074/jbc.M303488200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.

Authors:  Keith C Olsen; Amali P Epa; Ajit A Kulkarni; R Matthew Kottmann; Claire E McCarthy; Gail V Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

Review 2.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

3.  Transglutaminase 2 and its role in pulmonary fibrosis.

Authors:  Keith C Olsen; Ramil E Sapinoro; R M Kottmann; Ajit A Kulkarni; Siiri E Iismaa; Gail V W Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

4.  Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module.

Authors:  Xuening Wang; George P Studzinski
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

5.  Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway.

Authors:  Anna Janiak; Evgeny A Zemskov; Alexey M Belkin
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

6.  Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload.

Authors:  Arti V Shinde; Ya Su; Brad A Palanski; Kana Fujikura; Mario J Garcia; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2018-03-02       Impact factor: 5.000

7.  Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.

Authors:  Manuela Basso; Jill Berlin; Li Xia; Sama F Sleiman; Brendan Ko; Renee Haskew-Layton; Eunhee Kim; Marc A Antonyak; Richard A Cerione; Siiri E Iismaa; Dianna Willis; Sunghee Cho; Rajiv R Ratan
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

8.  Unconventional secretion of tissue transglutaminase involves phospholipid-dependent delivery into recycling endosomes.

Authors:  Evgeny A Zemskov; Irina Mikhailenko; Ru-Ching Hsia; Liubov Zaritskaya; Alexey M Belkin
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

Review 9.  Tissue transglutaminase in the pathogenesis of heart failure.

Authors:  Arti V Shinde; Nikolaos G Frangogiannis
Journal:  Cell Death Differ       Date:  2017-12-13       Impact factor: 15.828

10.  The role of Lutheran/basal cell adhesion molecule in human bladder carcinogenesis.

Authors:  Hong-Yi Chang; Hsin-Mei Chang; Tsung-Jung Wu; Chang-Yao Chaing; Tzong-Shin Tzai; Hong-Lin Cheng; Giri Raghavaraju; Nan-Haw Chow; Hsiao-Sheng Liu
Journal:  J Biomed Sci       Date:  2017-08-26       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.